<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852162</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ 2011-112</org_study_id>
    <nct_id>NCT01852162</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy</brief_title>
  <official_title>Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of
      treatment for prevention of atherothrombotic events in patients with coronary artery disease
      (CAD) undergoing percutaneous coronary interventions (PCI). Many patients on dual
      antiplatelet therapy in this setting may be affected by other thromboembolic conditions, in
      particular atrial fibrillation, therefore having an indication to also receive oral
      anticoagulation for stroke prevention. Thus, a considerable percentage of patients are under
      &quot;triple therapy&quot; which consists of aspirin plus clopidogrel plus an oral anticoagulant. The
      ever raising population with CAD warranting triple therapy and the growing number of patients
      being treated with dabigatran underscores the importance of understanding the pharmacodynamic
      effects of this treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of
      treatment for prevention of atherothrombotic events in patients with coronary artery disease
      (CAD) undergoing percutaneous coronary interventions (PCI). Many patients on dual
      antiplatelet therapy in this setting may be affected by other thromboembolic conditions, in
      particular atrial fibrillation, therefore having an indication to also receive oral
      anticoagulation for stroke prevention. Thus, a considerable percentage of patients are under
      &quot;triple therapy&quot; which consists of aspirin plus clopidogrel plus an oral anticoagulant.
      Although this combination therapy allows a reduction of atherothrombotic and thromboembolic
      events, patients on triple therapy are at an increased risk of bleeding complications.

      Dabigatran, a synthetic, reversible direct thrombin inhibitor, has been studied as an
      alternative to warfarin in patients with atrial fibrillation and has been shown to be at
      least as efficacious with a favorable safety profile. In particular, dabigatran at a dose of
      110 mg is associated with rates of stroke and systemic embolism similar to warfarin, with
      lower rates of major hemorrhage, while a dose of 150 mg is associated with lower thrombotic
      events with similar rates of bleeding events. These findings have led the Food and Drug
      Administration (FDA) to approve dabigatran for use in atrial fibrillation patients in
      December 2011 and this has also been implemented in practice guidelines to be a superior
      strategy to warfarin. However, the FDA only approved the 150mg formulation.

      Dabigatran has high affinity and specificity for its target serine protease thrombin, and one
      small study shows that dabigatran produced potent inhibition of thrombin-induced platelet
      aggregation in vitro. However, there are no studies assessing the ex vivo pharmacodynamic
      effects of dabigatran in patients on dual antiplatelet therapy. The ever raising population
      with CAD warranting triple therapy and the growing number of patients being treated with
      dabigatran underscores the importance of understanding the pharmacodynamic effects of this
      treatment regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TRAP-induced Platelet Aggregation</measure>
    <time_frame>1 week</time_frame>
    <description>TRAP-induced platelet aggregation measured by light transmittance aggregometry (LTA) was similar between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Measured by LTA</measure>
    <time_frame>1-week</time_frame>
    <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by light transmittance aggregometry (LTA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Measured by Multiple Electrode Aggregometry.</measure>
    <time_frame>1-week</time_frame>
    <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by multiple electrode aggregometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot Kinetic: Thrombin Activity</measure>
    <time_frame>1-week</time_frame>
    <description>Parameters related to thrombin activity and velocity of thrombus generation (reaction time: R; time to maximum rate of thrombus generation: TMRTG) were evaluated by thromboelastography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clot Kinetic: Clot Stength</measure>
    <time_frame>1-week</time_frame>
    <description>Clot strength (maximal amplitude:MA) was assessed by thromboelastography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran 150mg</description>
    <arm_group_label>Dabigatran</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with known CAD

          -  On maintenance treatment with aspirin (81 to 325mg per day) and clopidogrel (75 mg per
             day) for at least for at least 4-weeks as per standard of care.

          -  Age between 18 and 80 years old.

        Exclusion Criteria:

          -  Transient ischemic attack or ischemic stroke in the past 6 months.

          -  Prior hemorrhagic stroke (irrespective of timing).

          -  Known allergies to dabigatran.

          -  On treatment with Coumadin derivate or have an indication to be on Coumadin treatment
             (atrial fibrillation, prosthetic valve, DVT/pulmonary embolism).

          -  Platelet count &lt;80x106/mL

          -  Active bleeding or hemodynamic instability.

          -  Creatinine clearance &lt;30 mL/minute.

          -  Baseline ALT &gt;2.5 times the upper limit of normal.

          -  Hemoglobin &lt; 10 gm/dL

          -  Pregnant females*. *Women of childbearing age must use reliable birth control (i.e.
             oral contraceptives) while participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>anticoagulant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a prospective, randomized, double-blind, placebo-controlled PD study conducted in patients with CAD on maintenance DAPT with aspirin and clopidogrel. Patients were screened at the Division of Cardiology of the University Of Florida College Of Medicine - Jacksonville from February 2012 to December 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran</title>
          <description>Patients randomized to the dabigatran arm received dabigatran 150mg twice/daily for 7 (±3) days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients randomized to the placebo arm received matching placebo tablets twice/daily for 7 (±3) days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were considered for analysis of the PD end points if they completed both visits and had a compliance &gt;80% to study drug, clopidogrel and aspirin. All patients who received any dose of study medication were considered for analysis of safety and any other adverse events.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran</title>
          <description>Dabigatran 150mg tablets</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="8"/>
                    <measurement group_id="B2" value="59" spread="9"/>
                    <measurement group_id="B3" value="63" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TRAP-induced Platelet Aggregation</title>
        <description>TRAP-induced platelet aggregation measured by light transmittance aggregometry (LTA) was similar between groups</description>
        <time_frame>1 week</time_frame>
        <population>TRAP-induced platelet aggregation</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>TRAP-induced Platelet Aggregation</title>
          <description>TRAP-induced platelet aggregation measured by light transmittance aggregometry (LTA) was similar between groups</description>
          <population>TRAP-induced platelet aggregation</population>
          <units>percentage of aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="8"/>
                    <measurement group_id="O2" value="77" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assuming a 20% relative difference in TRAP induced MPA between dabigatran and placebo with a common standard deviation of 10%, 13 patients with available data needed to be randomized to obtain a 95% power and 2-sided alpha=0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>An analysis of covariance (ANCOVA) method with a general linear model, using the corresponding baseline PD value as a covariate, was used to evaluate the comparisons between dabigatran and placebo at 7 days.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Measured by LTA</title>
        <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by light transmittance aggregometry (LTA).</description>
        <time_frame>1-week</time_frame>
        <population>Platelet aggregation measured by LTA</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Measured by LTA</title>
          <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by light transmittance aggregometry (LTA).</description>
          <population>Platelet aggregation measured by LTA</population>
          <units>percentage of aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADP-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" spread="16.6"/>
                    <measurement group_id="O2" value="44.6" spread="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachidonic acid-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="18.2"/>
                    <measurement group_id="O2" value="6.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Collagen-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" spread="22.8"/>
                    <measurement group_id="O2" value="34.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Measured by Multiple Electrode Aggregometry.</title>
        <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by multiple electrode aggregometry.</description>
        <time_frame>1-week</time_frame>
        <population>Platelet aggregation measured by multiple electrode aggregometry.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Measured by Multiple Electrode Aggregometry.</title>
          <description>Multiple measures of platelet reactivity evaluating purinergic and non-purinergic signaling pathways were assessed by multiple electrode aggregometry.</description>
          <population>Platelet aggregation measured by multiple electrode aggregometry.</population>
          <units>arbitrary aggregation units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TRAP-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1176.4" spread="274"/>
                    <measurement group_id="O2" value="1210.6" spread="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADP-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482.2" spread="199"/>
                    <measurement group_id="O2" value="454.0" spread="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arachidonic acid-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.9" spread="88"/>
                    <measurement group_id="O2" value="230.1" spread="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Collagen-induced platelet aggregation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="559.4" spread="180"/>
                    <measurement group_id="O2" value="532.5" spread="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clot Kinetic: Thrombin Activity</title>
        <description>Parameters related to thrombin activity and velocity of thrombus generation (reaction time: R; time to maximum rate of thrombus generation: TMRTG) were evaluated by thromboelastography.</description>
        <time_frame>1-week</time_frame>
        <population>Clot kinetic assessed by citrated-kaolin thromboelastography</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Clot Kinetic: Thrombin Activity</title>
          <description>Parameters related to thrombin activity and velocity of thrombus generation (reaction time: R; time to maximum rate of thrombus generation: TMRTG) were evaluated by thromboelastography.</description>
          <population>Clot kinetic assessed by citrated-kaolin thromboelastography</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>R</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.25" spread="2.6"/>
                    <measurement group_id="O2" value="6.76" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TMRTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.32" spread="3"/>
                    <measurement group_id="O2" value="8.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clot Kinetic: Clot Stength</title>
        <description>Clot strength (maximal amplitude:MA) was assessed by thromboelastography.</description>
        <time_frame>1-week</time_frame>
        <population>Clot kinetic assessed by citrated-kaolin thromboelastography</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran</title>
            <description>Dabigatran 150mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Clot Kinetic: Clot Stength</title>
          <description>Clot strength (maximal amplitude:MA) was assessed by thromboelastography.</description>
          <population>Clot kinetic assessed by citrated-kaolin thromboelastography</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="4.4"/>
                    <measurement group_id="O2" value="62.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran</title>
          <description>Dabigatran 150mg tablets</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <description>One patient in the dabigatran group had a non-ST-segment elevation myocardial infarction during study treatment, which was medically managed and required study drug discontinuation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominick Angiolillo, MD, PhD</name_or_title>
      <organization>University of Florida</organization>
      <phone>904-244-3933</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

